$DRIO
DarioHealth Corp.

2019 Q1 Form 10-K Financial Statement

#000114420419015691 Filed on March 25, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $2.242M $1.700M $7.394M
YoY Change 27.68% 7.59% 43.02%
Cost Of Revenue $1.684M $1.480M $5.629M
YoY Change 39.87% 46.53% 45.87%
Gross Profit $558.0K $220.0K $1.765M
YoY Change 1.09% -61.4% 34.63%
Gross Profit Margin 24.89% 12.94% 23.87%
Selling, General & Admin $4.920M $4.450M $15.78M
YoY Change 80.22% 56.69% 26.95%
% of Gross Profit 881.72% 2022.73% 894.05%
Research & Development $1.002M $930.0K $3.676M
YoY Change 35.04% 9.41% 11.5%
% of Gross Profit 179.57% 422.73% 208.27%
Depreciation & Amortization $46.00K $50.00K $207.0K
YoY Change -13.21% 25.0% 6.15%
% of Gross Profit 8.24% 22.73% 11.73%
Operating Expenses $5.921M $5.380M $19.45M
YoY Change 70.78% 45.8% 23.67%
Operating Profit -$5.363M -$5.160M -$17.69M
YoY Change 83.98% 65.38% 22.67%
Interest Expense -$10.00K $170.0K -$120.0K
YoY Change 0.0% -101.93% -90.91%
% of Operating Profit
Other Income/Expense, Net -$13.00K -$115.0K
YoY Change 225.0% -91.31%
Pretax Income -$5.380M -$4.980M -$3.801M
YoY Change 84.25% -58.22% -26.11%
Income Tax
% Of Pretax Income
Net Earnings -$5.376M -$4.980M -$17.80M
YoY Change 84.17% -58.22% 13.09%
Net Earnings / Revenue -239.79% -292.94% -240.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.924M -$2.895M -$15.21M
COMMON SHARES
Basic Shares Outstanding 36.82M 25.94M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.100M $11.20M $11.18M
YoY Change -1.39% 180.0% 180.9%
Cash & Equivalents $6.958M $11.00M $11.00M
Short-Term Investments $200.0K $200.0K $180.0K
Other Short-Term Assets $66.00K
YoY Change -56.86%
Inventory $1.924M $1.377M $1.380M
Prepaid Expenses
Receivables $300.0K $200.0K $170.0K
Other Receivables $500.0K $600.0K $590.0K
Total Short-Term Assets $9.864M $13.31M $13.31M
YoY Change 10.83% 120.2% 120.0%
LONG-TERM ASSETS
Property, Plant & Equipment $732.0K $733.0K $730.0K
YoY Change -8.5% -15.65% -16.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $40.00K
YoY Change 0.0%
Total Long-Term Assets $1.569M $776.0K $780.0K
YoY Change 74.33% -14.82% -14.29%
TOTAL ASSETS
Total Short-Term Assets $9.864M $13.31M $13.31M
Total Long-Term Assets $1.569M $776.0K $780.0K
Total Assets $11.43M $14.09M $14.09M
YoY Change 16.66% 102.52% 102.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $2.600M $2.570M
YoY Change 172.73% 36.84% 38.92%
Accrued Expenses $300.0K $880.0K
YoY Change 105.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.018M $5.164M $5.160M
YoY Change 192.42% 71.28% 70.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $0.00 $0.00
YoY Change
Total Long-Term Liabilities $600.0K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.018M $5.164M $5.160M
Total Long-Term Liabilities $600.0K $0.00 $0.00
Total Liabilities $7.600M $5.200M $5.160M
YoY Change 216.67% 73.33% 70.86%
SHAREHOLDERS EQUITY
Retained Earnings -$94.63M -$89.25M
YoY Change 25.78%
Common Stock $8.000K $8.000K
YoY Change 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.865M $8.925M $8.930M
YoY Change
Total Liabilities & Shareholders Equity $11.43M $14.09M $14.09M
YoY Change 16.66% 102.52% 102.44%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$5.376M -$4.980M -$17.80M
YoY Change 84.17% -58.22% 13.09%
Depreciation, Depletion And Amortization $46.00K $50.00K $207.0K
YoY Change -13.21% 25.0% 6.15%
Cash From Operating Activities -$3.987M -$3.440M -$11.47M
YoY Change 44.14% 43.33% 8.01%
INVESTING ACTIVITIES
Capital Expenditures $45.00K -$20.00K $71.00K
YoY Change 275.0% -85.71% -63.59%
Acquisitions
YoY Change
Other Investing Activities -$10.00K $10.00K $80.00K
YoY Change -114.29% -200.0% -500.0%
Cash From Investing Activities -$52.00K -$10.00K $6.000K
YoY Change -194.55% -92.86% -102.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.020M 18.74M
YoY Change -100.0% -30300.0% 39.22%
NET CHANGE
Cash From Operating Activities -3.987M -3.440M -11.47M
Cash From Investing Activities -52.00K -10.00K 6.000K
Cash From Financing Activities 0.000 3.020M 18.74M
Net Change In Cash -4.039M -430.0K 7.279M
YoY Change -221.55% -83.14% 177.3%
FREE CASH FLOW
Cash From Operating Activities -$3.987M -$3.440M -$11.47M
Capital Expenditures $45.00K -$20.00K $71.00K
Free Cash Flow -$4.032M -$3.420M -$11.54M
YoY Change 45.14% 51.33% 6.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10997000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3718000
CY2018Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
180000
CY2017Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
258000
CY2018Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
168000
CY2017Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
282000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
591000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
604000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
13313000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
6046000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
43000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2018Q4 us-gaap Assets
Assets
14089000
CY2017Q4 us-gaap Assets
Assets
6957000
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2574000
CY2017Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1852000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
736000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5164000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3015000
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98171000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
74892000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89254000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70958000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8925000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3941000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14089000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6957000
CY2018 drio Bank Charges
BankCharges
18000
CY2017 drio Bank Charges
BankCharges
171000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-98000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1168000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-115000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1324000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36607755
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14074238
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36607755
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14074238
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
56000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Revenues
Revenues
7394000
CY2017 us-gaap Revenues
Revenues
5170000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5629000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3859000
CY2018 us-gaap Gross Profit
GrossProfit
1765000
CY2017 us-gaap Gross Profit
GrossProfit
1311000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3676000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3297000
CY2018 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10309000
CY2017 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
7707000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5468000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4726000
CY2018 us-gaap Operating Expenses
OperatingExpenses
19453000
CY2017 us-gaap Operating Expenses
OperatingExpenses
15730000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-17688000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-14419000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-116000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-156000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-17803000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15743000
CY2018 drio Deemed Dividend
DeemedDividend
-493000
CY2017 drio Deemed Dividend
DeemedDividend
-255000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18296000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15998000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.78
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.64
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23412891
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9628256
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-6541000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-17803000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-15743000
CY2018 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3758000
CY2017 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3824000
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-114000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
193000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
295000
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
722000
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
39000
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
977000
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
334000
CY2018 drio Revaluation Of Short Term Restricted Bank Deposits
RevaluationOfShortTermRestrictedBankDeposits
0
CY2017 drio Revaluation Of Short Term Restricted Bank Deposits
RevaluationOfShortTermRestrictedBankDeposits
17000
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-31000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11470000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10619000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
736000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2018 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-78000
CY2017 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
17000
CY2018 drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
1000
CY2017 drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
7000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-219000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3758000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3824000
CY2018 drio Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
18743000
CY2017 drio Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13463000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18743000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13463000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7279000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2625000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1093000
CY2018 drio Payment For Executives And Directors Under Salary Program
PaymentForExecutivesAndDirectorsUnderSalaryProgram
201000
CY2017 drio Payment For Executives And Directors Under Salary Program
PaymentForExecutivesAndDirectorsUnderSalaryProgram
183000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1378160
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.39
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
437000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
660068
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.94
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
60981
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.08
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
189446
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.38
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1787801
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.59
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
368000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1640510
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.61
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
367000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1261914
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.11
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
364000
CY2018 drio Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
0
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y3M25D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y11M23D
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11470000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 54pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; background: none; line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 18pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">a.</div></div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Use of estimates:</div></div></td></tr></table><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.79in; margin-top: 0px; text-align: justify; text-indent: -0.79in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP and&#160;</div>requires&#160;<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">the Company&#8217;s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management believes the Company&#8217;s critical accounting policies and estimates are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Revenue Recognition Software
RevenueRecognitionSoftware
<div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 54pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; background: none; line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 18pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">j.</div></div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition:</div></div></td></tr></table><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.19in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenues from product sales are recognized in accordance with ASC 605-10 &#8220;Revenue Recognition&#8221;, when delivery has occurred, persuasive evidence of an agreement exists, the vendor&#8217;s fee is fixed or determinable, no further obligation exists and collectability is probable.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;">&#160;</div><div style="font-family: &quot;times new roman&quot;, serif; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company derives revenues from the sale of its&#160;devices and its related device-specific disposables test strip cartridges and lancets through independent distributors or directly to end users. The Dario software application is offered for a free download and the Company does not obtain a recurring hosting commitment towards the end users relating specifically to the application.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company generally has a standard contract with its distributors. According to the agreements, all sales to distributors are final, no rights of return or price protection right is granted to such distributors and the Company is not a party of the agreements between distributors and their customers.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">When a sales arrangement contains multiple elements, such as services and products, the Company allocates revenue to each element based on a selling price hierarchy as required according to ASC 605-25, &#8220;Multiple-Element Arrangements&#8221;. The selling price for a deliverable is based on its Vendor Specific Objective Evidence (&#8220;VSOE&#8221;), if available, third party evidence (&#8220;TPE&#8221;) if VSOE is not available, or estimated selling price (&#8220;ESP&#8221;) if neither VSOE nor TPE is available. The best estimate of selling price is established considering several internal factors including, but not limited to, historical sales, pricing practices and geographies in which the Company offers its products.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Revenues from services are&#160;recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred or the services have been rendered, the fee is fixed or determinable and collectability is probable.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 54pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; background: none; line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 18pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">l.</div></div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of credit risk:</div></div></td></tr></table><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div><div style="clear: both; max-height: 0px;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term bank deposits and trade receivables.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">All of the cash and cash equivalents and short-term bank deposits of the Company and its Subsidiary are invested in deposits and current accounts with major U.S. and Israeli banks. Such cash and cash equivalents and short-term bank deposits may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents and short-term bank deposits may be redeemed and therefore a minimal credit risk exists with respect to these deposits and investments.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s trade receivables are derived mainly from sales to distributers and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.18in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18168645
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1787801
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1434924
CY2018 drio Percentage Of Monthly Deposits Behalf Of Insurance Companies
PercentageOfMonthlyDepositsBehalfOfInsuranceCompanies
0.0833
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
41000
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
190000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017 drio Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
0
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1294000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
819000
CY2017 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2017 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
0
CY2018 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1173000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1346000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
440000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
477000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
733000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
869000
CY2018 us-gaap Depreciation
Depreciation
207000
CY2017 us-gaap Depreciation
Depreciation
195000
CY2017 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1514000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
302000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
258000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
228000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
197000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
985000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
351000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
301000
CY2018 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1786000
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
874000
CY2018 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
504000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10294000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10794000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
791000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
620000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11085000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11414000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11085000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11414000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3801000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5144000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-14002000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10599000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17803000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15743000
CY2017 drio Stock Issued During Period Private Placement Value New Issues March2017
StockIssuedDuringPeriodPrivatePlacementValueNewIssuesMarch2017
1878000
CY2017 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
8655000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
47233000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
329000
CY2017 drio Stock Issued During Period Public Offering Value New Issues April2017
StockIssuedDuringPeriodPublicOfferingValueNewIssuesApril2017
3855000
CY2017 drio Issuance Of Common Stock In August2017 Private Placement Net Of Issuance Cost
IssuanceOfCommonStockInAugust2017PrivatePlacementNetOfIssuanceCost
801000
CY2017 drio Preferred Stock Issued During Period Private Placement Value New Issues August2017
PreferredStockIssuedDuringPeriodPrivatePlacementValueNewIssuesAugust2017
3711000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2017 drio Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.23
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.24
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1333333
CY2016Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1333333
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.50
CY2016Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5038000
CY2016Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
974000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
880000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
428000
CY2018Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1854000
CY2017Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
1163000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
454000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
451000
CY2018Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
71000
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
66000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
153000
CY2018Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
424000
CY2017Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
323000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
953000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
861000
CY2018Q4 us-gaap Inventory Net
InventoryNet
1377000
CY2017Q4 us-gaap Inventory Net
InventoryNet
1184000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2016Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
300000
CY2016Q3 drio Warrant Exercise Period
WarrantExercisePeriod
P4Y6M
CY2016 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
702000
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.50
CY2018 drio Issuance Of Common Stock In August2017 Private Placement Net Of Issuance Cost
IssuanceOfCommonStockInAugust2017PrivatePlacementNetOfIssuanceCost
9354000
CY2018 drio Preferred Stock Issued During Period Private Placement Value New Issues August2017
PreferredStockIssuedDuringPeriodPrivatePlacementValueNewIssuesAugust2017
9269000
CY2017Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.34
CY2017Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5100000
CY2017Q1 drio Stock Issued During Period Shares New Issues February2014
StockIssuedDuringPeriodSharesNewIssuesFebruary2014
1821437
CY2017Q4 drio Service Fees Payable
ServiceFeesPayable
298000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1450000
CY2017Q2 drio Stock Issued Price Per Share
StockIssuedPricePerShare
3.10
CY2017Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3855000
CY2017Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
36250
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.875
CY2017Q4 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
255000
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1871436
CY2017Q4 drio Class Of Warrant Or Right Aggregate With Shares Consideration
ClassOfWarrantOrRightAggregateWithSharesConsideration
1039676
CY2018Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6034000
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1020357
CY2018Q2 drio Class Of Warrant Or Right Aggregate With Shares Consideration
ClassOfWarrantOrRightAggregateWithSharesConsideration
636752
CY2018Q2 drio Deemed Dividend Related To Warrant Exchange Agreement
DeemedDividendRelatedToWarrantExchangeAgreement
493000
CY2018Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7561028
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.90
CY2018Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3050000000
CY2018Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
3050000
CY2018Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3050000
CY2018Q3 us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
8000
CY2018 us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
369993
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
504
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.56
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.07
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3023000
CY2017 drio Stock Issued During Period Private Placement Value New Issues January2017
StockIssuedDuringPeriodPrivatePlacementValueNewIssuesJanuary2017
2936000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
707000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1055000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q4 drio Percentage Of Income To Be Offset By Net Operating Loss Carry Forwards
PercentageOfIncomeToBeOffsetByNetOperatingLossCarryForwards
0.8
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.34
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
572000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M20D
CY2018Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
45000
CY2018Q4 us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
26250
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y3M25D
CY2018 drio Increase Decrease In Other Receivables And Prepaid Expense
IncreaseDecreaseInOtherReceivablesAndPrepaidExpense
-13000
CY2017 drio Increase Decrease In Other Receivables And Prepaid Expense
IncreaseDecreaseInOtherReceivablesAndPrepaidExpense
99000
CY2018 drio Reclassifiacation Of Warrants From Liability To Equity
ReclassifiacationOfWarrantsFromLiabilityToEquity
0
CY2017 drio Reclassifiacation Of Warrants From Liability To Equity
ReclassifiacationOfWarrantsFromLiabilityToEquity
8655000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
DarioHealth Corp.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001533998
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
20786954
CY2018 dei Trading Symbol
TradingSymbol
DRIO
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36821173
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 drio Right Of Use Assets And Lease Liabilities Carrying Amount
RightOfUseAssetsAndLeaseLiabilitiesCarryingAmount
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
1965000

Files In Submission

Name View Source Status
0001144204-19-015691-index-headers.html Edgar Link pending
0001144204-19-015691-index.html Edgar Link pending
0001144204-19-015691.txt Edgar Link pending
0001144204-19-015691-xbrl.zip Edgar Link pending
drio-20181231.xml Edgar Link completed
drio-20181231.xsd Edgar Link pending
drio-20181231_cal.xml Edgar Link unprocessable
drio-20181231_def.xml Edgar Link unprocessable
drio-20181231_lab.xml Edgar Link unprocessable
drio-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv515563_10k.htm Edgar Link pending
tv515563_ex21-1.htm Edgar Link pending
tv515563_ex23-1.htm Edgar Link pending
tv515563_ex31-1.htm Edgar Link pending
tv515563_ex31-2.htm Edgar Link pending
tv515563_ex32-1.htm Edgar Link pending
tv515563_img01.jpg Edgar Link pending